News & Updates
Filter by Specialty:
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
04 Sep 2025
Quitting smoking may help recovery from substance use disorders
Smoking cessation is associated with sustained recovery from substance use disorders (SUDs), according to a longitudinal cohort study funded by the US National Institutes of Health (NIH).
Quitting smoking may help recovery from substance use disorders
04 Sep 2025
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
03 Sep 2025
Ileostomy reversal after rectal cancer surgery: Does timing matter?
In a systematic review and meta-analysis evaluating surgical outcomes in low rectal cancer patients who underwent early vs late ileostomy reversal, the former appears to be less beneficial than the latter in terms of surgical complications.